Is DiGA Worth the Investment for HealthTech Startups?

Is DiGA worth considering as a distribution and go-to-market channel for digital health products? In this discussion, Ralf-Gordon Jahns shares key figures on DiGA, followed by insights from our product team, represented by Evghenii Cucias, on what really matters beyond approval: product quality, traceability, medical evidence, QMS, CE marking, and readiness for market access. Thanks to R2GConnect for bringing this discussion together with Raquel Cunha from CoLAB TRIALS, Benjamin Broll, Miriam Schulze of BAYOOMED, and Eric A. Behrendt of TÜV Informationstechnik GmbH.